A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Desai J, Wagner AJ, Carrasco Garcia I, Cesari M, Gordon M, Lin CC, Papai Z, Ryan CW, Tap WD, Trent JC, Gelderblom H, Grimison P, López Pousa A, Van Tine BA, Rubinacci M, Dai D, Rajper AW, Tecson K, Wooddell M, Stacchiotti S.
Desai J, et al. Among authors: ryan cw.
Cancer. 2024 Nov 12. doi: 10.1002/cncr.35634. Online ahead of print.
Cancer. 2024.
PMID: 39533157